Intestinal permeability is increased in ex-premature children with a history of intrauterine growth retardation

2017 ◽  
Vol 49 (4) ◽  
pp. e284-e285
Author(s):  
V. Giorgio ◽  
G. Margiotta ◽  
I. Venezia ◽  
G. Giarrusso ◽  
F. Lecci ◽  
...  
Keyword(s):  
Intestinal Permeability ◽  
Growth Retardation ◽  
Intrauterine Growth Retardation ◽  
Intrauterine Growth ◽  
History Of ◽  
Premature Children

Differential Effects of Maternal Heroin and Methadone Use on Birthweight

PEDIATRICS ◽  
1976 ◽  
Vol 58 (5) ◽  
pp. 681-685
Author(s):  
Stephen R. Kandall ◽  
Susan Albin ◽  
Joyce Lowinson ◽  
Beatrice Berle ◽  
Arthur I. Eidelman ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Growth Retardation ◽  
Intrauterine Growth Retardation ◽  
Methadone Maintenance ◽  
First Trimester ◽  
Control Group ◽  
Fetal Growth Retardation ◽  
Intrauterine Growth ◽  
Methadone Dosage ◽  
History Of

An analysis of birthweights of 337 neonates in relation to history of maternal narcotic usage was undertaken Mean birthweight of infants born to mothers abusing heroin during the pregnancy was 2,490 gm, an effect primarily of intrauterine growth retardation. Low mean birthweight (2,615 gm) was also seen in infants born to mothers who had abused heroin only prior to this pregnancy, and mothers who had used both heroin and methadone during the pregnancy (2,535 gm). Infants born to mothers on methadone maintenance during the pregnancy had significantly higher mean birthweights (2,961 gm), but lower than the control group (3,176 gm). A highly significant relationship was observed between maternal methadone dosage in the first trimester and birthweight, i.e., the higher the dosage, the larger the infant. Heroin causes fetal growth retardation, an effect which may persist beyond the period of addiction. Methadone may promote fetal growth in a dose-related fashion after maternal use of heroin.

scholarly journals Management and Outcome of 11 Pregnancies in Women with Polycythemia Vera

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5471-5471
Author(s):  
Elena Maria Elli ◽  
Rossella Calori ◽  
Ida Carmosino ◽  
Massimo Breccia ◽  
Elisa Diral ◽  
...  
Keyword(s):  
Polycythemia Vera ◽  
Growth Retardation ◽  
Intrauterine Growth Retardation ◽  
Post Partum ◽  
Fetal Loss ◽  
Childbearing Age ◽  
Maternal Complications ◽  
Intrauterine Growth ◽  
Fetal Complications ◽  
History Of

Abstract Background : Unlike to Essential Thrombocythemia, Polycythemia Vera (PV) is rare in women of childbearing age, with only few previous pregnancies reported in literature; a positive outcome of pregnancy has been described in about 2/3 of cases and maternal complications in about 1/4 of delivery. Aims and Methods : We retrospectively analyzed outcome and complications in a series of 11 pregnancies in 7 females with PV. These patients were diagnosed and managed between 2000 and 2017 in 3 Italian Centers. PV diagnosis was perfomed or revised according to WHO 2016 criteria. Different therapeutic approaches have been assessed prior and during each pregnancy. Results : Median age at diagnosis and at conception were 24.3 and 30.1 years, respectively. According to molecular status, all patients presented JAK2V617F mutations. Four patients (57.1%) had two pregnancies. All patients received phlebotomies as required, with a median hematocrit (Ht) level at the time of conception of 45.2% (range: 41.4-46.8). Median values of WBC and PLT at conception were 9.9 x 109/l (range: 6.7-18.3) and 510 x 109/l (250-917). Only one patient presented a history of thrombosis (2 TIA) occurred before first pregnancy. Three (42.8%) females presented cardiovascular risk factors at the time of conception, while a thrombophilic predisposition was documented in 3 patients (42.8%). Among the 11 pregnancies, 8 (72.7%) ended with a full term delivery, while 2 (18.2%) were complicated by a fetal loss in the first trimester and by an Intrauterine growth retardation with preterm delivery. It is worth of note that the fetal loss was reported in the patient with prior arterial thrombosis and concomitant signs of myeloproliferation (mild leukocytosis, Ht level > 45% and PLT level > 900 x 109/l), while the intrauterine growth retardation was reported in a patient with Ht level > 45%, despite the typical hemodiluition of pregnancy. The remaining pregnancy was characterized by maternal complications, consisting of an extra-tubal pregnancy with consequent laparoscopic surgery approach and fetal death. The global live birth rate was 81.8 %. Anti-thrombotic treatment was administered in all but one pregnancy, consisting of low-dose acetil salicylic acid (ASA) already started since PV diagnosis and continued during pregnancy in 6 pregnancies (54.5%), or a combination of ASA and Low Molecular Weight Heparin (LMWH) during the second and last trimester of pregnancy and post-partum in the remaining 4 pregnancies (36.3%). Two patients were also treated with interferon-alfa during their pregnancy. One patient was receiving hydroxyurea at the time of conception, which was immediately stopped. Conclusions : Our data indicate that PV patients may develop pregnancy complications in about 1/4 of cases (27.2%), but the risk of fetal loss (18.2%) is lower than recently reported in similar series of PV females. The vast majority of our patients received ASA +/- LMWH during pregnancy and post-partum, suggesting an important role of anti-thrombotic treatment in reducing incidence of fetal complications. The history of prior thrombosis and the signs of myeloproliferation at conception and at delivery seem to be associated to development of fetal complications. Considering the current guidelines for the management of PV, in particular the more aggressive control of Ht (with Ht target < 45%), it is possible that the large application of this approach also in PV pregnancies could further improve the rate of fetal complications. Larger collaborative multicenter studies, in order to better clarify the optimal management of pregnancy in PV, are warranted. Disclosures Breccia: Pfizer: Honoraria; BMS: Honoraria; Novartis: Honoraria; Incyte: Honoraria. Gambacorti-Passerini:Pfizer: Consultancy, Honoraria, Research Funding; BMS: Consultancy.

Massive Perivillous Fibrin Deposition and Chronic Histiocytic Intervillositis of a Placenta: Rare co-existence

2020 ◽  
Vol 154 (Supplement_1) ◽  
pp. S34-S34
Author(s):  
E Ozluk ◽  
J Cotelingam ◽  
M Ong
Keyword(s):  
African American ◽  
Spontaneous Abortion ◽  
Growth Retardation ◽  
Intrauterine Growth Retardation ◽  
African American Female ◽  
Fibrin Deposition ◽  
Literature Report ◽  
Intrauterine Growth ◽  
History Of ◽  
Histiocytic Infiltration

Abstract Introduction/Objective Massive perivillous fibrin deposition (MPFD) and chronic histiocytic intervillositis (CHI) of the placenta are both very rare entities individually. They both are associated with reccurent loss of the fetus. Methods Here we report a placenta with coexisting MPFD and CHI. Patient is a 24-year-old African American female who has a history of spontaneous abortion at the 10th week when she was 18. Her latest pregnancy is complicated by intrauterine growth retardation and she eventually losses the fetus at 20th week of gestation. Results Histopathology reveals extensive fibrin deposition of the perivillous area and the histiocytic infiltration of the intervillous spaces which is highlighted by CD68 staining. Conclusion This is the second literature report of a co-occurrence of MPFD and CHI to our knowledge. Pathologists must be familiar with these entities and inform the obstetricians because these placental lesions often result with recurrent loss of fetus.

scholarly journals "Intrauterine programming" of hormonal and metabolic processes and intrauterine growth retardation syndrome

2010 ◽  
Vol 56 (6) ◽  
pp. 32-40 ◽  
Author(s):  
E V Nagaeva ◽  
T Iu Shiriaeva
Keyword(s):  
Growth Retardation ◽  
Metabolic Disorders ◽  
Intrauterine Growth Retardation ◽  
Experimental Studies ◽  
Endocrine Diseases ◽  
Intrauterine Growth ◽  
Close Relationship ◽  
History Of ◽  
Elevated Arterial Pressure ◽  
Intrauterine Programming

According to the "intrauterine programming" hypothesis, the fetus responses to nutritional deficiency by adaptation in the form of long-standing changes of metabolism that eventually create predisposition to cardiovascular, metabolic, and endocrine diseases. Up to now, a wealth of catamnestic data have been gathered indicating that individuals having the history of growth retardation in the prenatal period are likely to develop a variety of hormonal and metabolic disorders when they reach their mature age. Specifically, there is the close relationship between the intrauterine growth retardation syndrome and elevated arterial pressure, impaired glucose tolerance, and metabolic syndrome. The present review summarizes the results of epidemiological and experimental studies that confirm the above hypothesis.

Imbalance in the system L-arginin-NO in pathogenesis of obstetric complications and intrauterine growth retardation (Literature review)

2016 ◽  
pp. 43-47
Author(s):  
O.V. Basystyi ◽  
Keyword(s):  
Nitric Oxide ◽  
Literature Review ◽  
Growth Retardation ◽  
Intrauterine Growth Retardation ◽  
Obstetric Complications ◽  
Pathogenetic Role ◽  
Intrauterine Growth ◽  
System L ◽  
Nitric Oxide Deficiency

The data of domestic and foreign literature on etiology, pathogenesis and intrauterine growth retardation diagnosis are presented in the paper. It highlights pathogenetic role of nitric oxide deficiency in case of obstetric complications and intrauterine growth retardation. Key words: intrauterine growth retardation (IUGR), system L-arginin–NO, obstetric complications.

Sign in / Sign up

Export Citation Format

Share Document